Key result
Duct stenting in hybrid stage-1 palliation yields <3% procedural mortality for duct-dependent systemic circulation.
Why the study?
As arterial duct stenting has expanded to hybrid and complete transcatheter strategies for HLHS, bi-ventricular lesions, and pulmonary hypertension, a contemporary assessment of its strengths, weaknesses, and complications is needed.
Percutaneous ductal stenting as part of a hybrid or fully transcatheter stage-1 strategy offers a less traumatic, anesthesia-sparing alternative to neonatal Norwood surgery for infants with duct-dependent systemic blood flow, though it requires meticulous peri-procedural and interstage management.
Answers are grounded in this paper and cite their sources.
Supports ductal stenting as less invasive palliation in select neonates; leaves open need for randomized trials versus Norwood surgery.
Arterial duct stenting, pioneered in the early 1990s for newborns with a duct-dependent pulmonary and systemic circulation, has evolved significantly over the past decades. This progressive technique has led to the development of novel therapeutic strategies, including the Hybrid approach introduced three decades ago, and more recently, a complete transcatheter approach for treating newborns with hypoplastic left heart syndrome (HLHS). Subsequently, the transcatheter method has been extended to bi-ventricular lesions and patients with pulmonary hypertension, establishing a reverse Potts-shunt pathophysiology. Considering current experiences, this review aims to assess the strengths, weaknesses, and complications associated with ductal stenting, which represents a critical component of these complex treatment strategies. Despite advancements, the mortality rate of Norwood and Hybrid stage-1 procedures has plateaued, underscoring the importance of enhancing the quality of life of affected patients as the primary therapeutic goal. The prerequisite is a gentle, almost atraumatic medicine, particularly during the newborn period. It is essential to recognize that both the Hybrid and total transcatheter approaches demand comparable experience to Norwood surgery. Successful outcomes hinge on much more than merely inserting a stent into the duct; they require meticulous attention to detail and comprehensive management strategies.
No takes yet. Share an insight, caveat, or question.
Dietmar Schranz (2024) conducted a review in Duct-dependent systemic blood flow, including hypoplastic left heart syndrome (HLHS), hypoplastic left heart complex (HLHC), borderline left ventricle, and suprasystemic pulmonary arterial hypertension. Arterial duct stenting (as part of the Hybrid approach or complete transcatheter DIDI approach) vs. Norwood stage-1 surgery was evaluated. Arterial duct stenting in hybrid or transcatheter stage-1 procedures achieves <3% procedural mortality and 5-10% interstage mortality in neonates with duct-dependent systemic circulation.
Synapse has enriched 10 related papers. Consider them for comparative context: